Encoded Therapeutics has officially closed a massive $275 million Series F financing round, marking a critical financial milestone for the…
Read More
Inflammatory Remodeling of the Bone Marrow Niche: New Insights into the Early Drivers of Clonal Hematopoiesis and Myelodysplastic Syndrome
The human bone marrow serves as a prolific biological factory, generating millions of new blood and immune cells every second…
Read More
Gene Therapy Shows Significant Promise in Reversing Fragile X Syndrome Deficits in Mice, Offering Hope for Human Treatment
A groundbreaking study led by the University of California, Riverside (CA, USA) has demonstrated that a novel gene therapy successfully…
Read More
A Coordinated Medical Approach for Cardiovascular-Kidney-Metabolic Syndrome: A New Clinical Guideline
A landmark clinical guideline, published on June 9th in the esteemed journal Circulation, heralds a significant paradigm shift in the…
Read More
Arrowhead Pharmaceuticals Secures Australian TGA Approval for Redemplo, Offering Hope for Familial Chylomicronemia Syndrome Patients
The Australian Therapeutic Goods Administration (TGA) has granted approval for Arrowhead Pharmaceuticals’ Redemplo (plozasiran), a novel therapeutic agent designed to…
Read More
Molecular Mapping of Bone Marrow Remodeling Reveals Early Inflammatory Drivers of Blood Cancer and Myelodysplastic Syndrome
The human bone marrow is one of the most industrious environments in the human body, a cellular factory that generates…
Read More
Researchers Identify Experimental Strategy to Boost MeCP2 Protein Levels as Potential Therapy for Rett Syndrome
A collaborative research team at the Texas Children’s Duncan Neurological Research Institute (NRI) and Baylor College of Medicine has unveiled…
Read More
